psav Search Results


psav  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare psav
Psav, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psav/psav/pm22781432-23-0-21
Average 90 stars, based on 1 article reviews
psav - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
psav calculations  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare psav calculations
Study design shows timing of biopsies, PSA testing and periods for successive <t>PSAV</t> calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in <t>Johns</t> <t>Hopkins</t> AS Program from 1995 to 2012.
Psav Calculations, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psav/psav+calculations/pmc04711358-194-16-19
Average 90 stars, based on 1 article reviews
psav calculations - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Study design shows timing of biopsies, PSA testing and periods for successive PSAV calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

Journal: The Journal of urology

Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

doi: 10.1016/j.juro.2013.09.029

Figure Lengend Snippet: Study design shows timing of biopsies, PSA testing and periods for successive PSAV calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

Techniques:

PSAV in men with 3 serial PSAV measurements (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

Journal: The Journal of urology

Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

doi: 10.1016/j.juro.2013.09.029

Figure Lengend Snippet: PSAV in men with 3 serial PSAV measurements (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

Techniques:

Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012

Journal: The Journal of urology

Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

doi: 10.1016/j.juro.2013.09.029

Figure Lengend Snippet: Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012

Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

Techniques:

Cumulative incidence of unfavorable biopsies by RC during followup in men with 3 serial PSAV calculations in Johns Hopkins AS Program from 1995 to 2012.

Journal: The Journal of urology

Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

doi: 10.1016/j.juro.2013.09.029

Figure Lengend Snippet: Cumulative incidence of unfavorable biopsies by RC during followup in men with 3 serial PSAV calculations in Johns Hopkins AS Program from 1995 to 2012.

Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

Techniques:

ROC analysis of base logistic regression model vs models with addition of overall PSAV or PSAV RC for outcomes of biopsy reclassification by any criteria (A) and specifically Gleason score reclassification (GSR) (B) in Johns Hopkins AS Program from 1995 to 2012.

Journal: The Journal of urology

Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

doi: 10.1016/j.juro.2013.09.029

Figure Lengend Snippet: ROC analysis of base logistic regression model vs models with addition of overall PSAV or PSAV RC for outcomes of biopsy reclassification by any criteria (A) and specifically Gleason score reclassification (GSR) (B) in Johns Hopkins AS Program from 1995 to 2012.

Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

Techniques: